AC Immune SA Form 6-K Summary
Business Context and Reporting Period
This Form 6-K covers the month of April 2026 for AC Immune SA, a foreign private issuer based in Lausanne, Switzerland. The filing reports on a strategic amendment to a collaboration agreement with Eli Lilly and Company regarding the research and development of Tau aggregation inhibitor small molecules for Alzheimer's disease and other neurodegenerative conditions.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics for the period. The only specific financial figures disclosed relate to the new agreement:
- Upfront Payment: CHF 10 million.
- Immediate Milestone: A subsequent payment upon Phase 1 dosing.
- Future Potential: Eligibility for over CHF 1.7 billion in development, regulatory, and commercial milestones, plus tiered royalty payments in the low double digits.
Material Changes
The primary material change is the amendment to the License Agreement originally dated December 11, 2018, and previously amended on March 20, 2020. This amendment secures immediate cash inflow (CHF 10 million) and establishes a new milestone trigger for Phase 1 dosing, building upon the existing framework of potential future payments.
Outlook, Risks, and Management Commentary
Management highlights the continued partnership with Eli Lilly to advance Tau aggregation inhibitors. The filing notes that the descriptions of the Amendment in this report and the attached press release are not complete and are qualified by reference to the full text of the Amendment, which will be filed as an exhibit to a future SEC filing. No specific risks or contingencies beyond the standard qualification of the agreement text are detailed in this summary.
Key Facts for Investor Verification
- Verify the exact terms and conditions of the Phase 1 dosing milestone payment.
- Confirm the timeline for the filing of the full Amendment text as an exhibit to a future SEC filing.
- Assess the impact of the CHF 10 million upfront payment on the company's current cash runway.
- Review the specific criteria for the "low double digits" tiered royalty payments.